{
  "id": "5c8ab614d558e5f23200000d",
  "type": "yesno",
  "question": "Is the protein Asporin related to disease?",
  "ideal_answer": "Yes,\nAccumulating evidence demonstrates the involvement of asporin in OA pathogenesis. Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25689697",
    "http://www.ncbi.nlm.nih.gov/pubmed/27409832",
    "http://www.ncbi.nlm.nih.gov/pubmed/28152543",
    "http://www.ncbi.nlm.nih.gov/pubmed/27705916"
  ],
  "snippets": [
    {
      "text": "Accumulating evidence demonstrates the involvement of asporin in OA pathogenesis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25689697",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asporin has been reported as a tumor suppressor in breast cancer, while asporin-activated invasion has been described in gastric cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27409832",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Asporin has been implicated as an oncogene in various types of human cancers; ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " These results suggested that asporin promoted the tumor growth and metastasis of CRC, and it could be a potential therapeutic target for CRC patients in future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27705916",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results suggest that ASPN is a stromally expressed biomarker that correlates with disease progression, and is observed in reactive stroma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28152543",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}